本研究旨在以隨機方式，在接受三相對比CT的風險人群中，前瞻性驗證此AI演算法，並與現行放射學報告標準進行比較。本研究項目完全獨立，與當值放射科醫生實際的CT掃描臨床報告分開。
適應症：Hepatocellular Carcinoma
收案條件
納入條件
- \. Age \>=18 years.
- \. Defined as the at-risk population requiring regular liver ultrasonography surveillance.
- These include:
- Cirrhotic patients of any disease etiology,
- Chronic hepatitis B patients of age ≥40 years for men, age ≥50 years for women or with a family history of HCC.
- \. At least one new-onset focal liver nodule detected on liver ultrasonography.
排除條件
- \. Liver nodules of \<1 cm. Currently such nodules are not reported using LI-RADS criteria but are recommended for a repeat scan in 3-6 months. In patients with multiple liver nodules, the largest nodule will be assessed.
- \. Patients with contraindications for contrast CT imaging, including a history of contrast anaphylaxis and impaired renal function (glomerular filtration rate \<30 ml/min).
- \. Patients with prior transarterial chemoembolization or other interventional procedures with intrahepatic injection of lipiodol. Lipiodol is extremely hyperdense on computed tomography and will preclude objective interpretation. Such patients were also excluded in the development of our prototype AI algorithm.
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。